It is important to note that the specific Klow combination itself has not been systematically evaluated in clinical studies, and any observed effects in research models should not be interpreted as evidence of safety or efficacy in humans or animals
Issue: No measurable vision improvement after 3 months Potential causes: Unrealistic expectations (expecting improvement vs slowed decline), advanced disease with minimal salvageable tissue, inadequate dosing or inconsistent use, wrong peptide for specific condition, peptides genuinely ineffective for individual, progression monitoring inadequate missing subtle benefits
Lifestyle Modifications for Enhanced Results Peptide therapy does not operate in isolation
Poor sleep can increase NNMT expression and reduce NAD+ levels, potentially counteracting some benefits of 5-amino-1mq
The convenience of nasal spray delivery removes many barriers to consistent use, potentially improving outcomes through better adherence